Protalex Inc. (PRTX) Lifted to “Sell” at ValuEngine
ValuEngine upgraded shares of Protalex Inc. (OTCMKTS:PRTX) from a strong sell rating to a sell rating in a research note issued to investors on Wednesday.
Protalex (OTCMKTS PRTX) opened at 1.00 on Wednesday. Protalex has a 12 month low of $0.31 and a 12 month high of $3.00. The firm’s 50-day moving average is $0.67 and its 200 day moving average is $0.84. The firm’s market capitalization is $28.77 million.
Protalex, Inc is a clinical-stage company. The Company is focused on the development of a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and Immune Thrombocytopenia (ITP). The Company’s lead product candidate, PRTX-100, is a formulation of the Staphylococcal bacterial protein known as Protein A, which modifies aspects of the human immune system.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Stock Ratings for Protalex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalex Inc. and related stocks with our FREE daily email newsletter.